CPRX
NASDAQCatalyst Pharmaceuticals Inc.
Price$27.69+1.71 (+6.56%)
01:30 PM07:45 PM
News · 26 weeks60-100%
2025-10-262026-04-19
Mix990d
- Other3(33%)
- SEC Filings3(33%)
- Earnings2(22%)
- Insider1(11%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Catalyst Pharmaceuticals Inc.SCHEDULE 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)
- SECSEC Form 8-K filed by Catalyst Pharmaceuticals Inc.8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- PRCatalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific ConferenceCORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company will showcase real‑world findings in Duchenne muscular dystrophy (DMD) through multiple poster presentations at the 2026 MDA Clinical & Scientific Conference in Orlando, Florida. Catalyst will also sponsor a vamorolone-focused MDA Industry Forum with Santhera Pharmaceuticals. "The MDA meeting is a key opportunity to highlight the expanding real‑world evidence shaping
- SECSEC Form 8-K filed by Catalyst Pharmaceuticals Inc.8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- PRCatalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial GuidanceFull Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3% FIRDAPSE® (amifampridine) Growth and 67.5% Growth of AGAMREE® (vamorolone), Reflecting Continued Adoption Full Year 2026 Total Revenues Expected to be Between $615 Million and $645 Million, Reflecting Confidence in Strength and Durability of FIRDAPSE and AGAMREE Franchises Promoted Product Revenue, Net Expected to Grow by 20% or More in 2026 Conference Call and Webcast to be Held on February 26, 2026, at 8:30 AM ET CORAL GABLES, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuti
- SECSEC Form 10-K filed by Catalyst Pharmaceuticals Inc.10-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- PRCatalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare ConferenceCORAL GABLES, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026, being held in Miami, Florida. Presentation DetailsDate: Tuesday, March 10, 2026Presentation: 3:30 PM ETWebcast Link The webcast will be available under the Inv
- INSIDERChief HR Officer Russo Gregg covered exercise/tax liability with 211 shares and converted options into 687 shares (SEC Form 4)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- PRCatalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026CORAL GABLES, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its fourth quarter and full-year 2025 financial results after the market close on Wednesday, February 25, 2026. Catalyst's management team will host a conference call and webcast on Thursday, February 26, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast Details Date:February 26, 2026Tim
- SECCatalyst Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- PRCatalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap CompaniesCORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2026. Catalyst has ranked an impressive 11 out of 100 companies on the list. "We are honored to once again be recognized on Forbes' list of America's Most Successful Small-Cap Companies for 2026," said Rich Daly, President and CEO, Catalyst. "Our accomplishments over the p
- INSIDERExecutive Vice President & CFO Kalb Michael Wayne converted options into 7,139 shares and covered exercise/tax liability with 2,080 shares, increasing direct ownership by 59% to 13,665 units (SEC Form 4)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERPresident and CEO Daly Richard J covered exercise/tax liability with 10,577 shares and converted options into 42,105 shares, increasing direct ownership by 13% to 271,266 units (SEC Form 4)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- PRThe University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)CORAL GABLES, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The University of Notre Dame and Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced their inaugural Catalyst Advocacy Scholars Summit (CASS). This one-of-a-kind program was created with The University of Notre Dame's Patient Advocacy Minor Department to provide participating students with an immersive learning experience exploring the opportunities and challenges of delivering medicine to people living with rare diseases.
- INSIDERDirector Tierney David S converted options into 1,334 shares, increasing direct ownership by 0.35% to 383,314 units (SEC Form 4)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERChairman of Board of Directors Mcenany Patrick J converted options into 26,334 shares and covered exercise/tax liability with 6,786 shares, increasing direct ownership by 0.47% to 4,171,559 units (SEC Form 4)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERDirector Denkhaus Donald A converted options into 1,334 shares, increasing direct ownership by 0.27% to 498,773 units (SEC Form 4)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERChief Compliance/Legal Officer Elsbernd Brian converted options into 6,667 shares and covered exercise/tax liability with 2,623 shares, increasing direct ownership by 2% to 242,501 units (SEC Form 4)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERChief Op. & Scientific Officer Miller Steve converted options into 14,000 shares, increasing direct ownership by 1% to 1,093,803 units (SEC Form 4)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERDirector Harper Molly converted options into 1,334 shares, increasing direct ownership by 57% to 3,694 units (SEC Form 4)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERPresident and CEO Daly Richard J converted options into 1,334 shares and covered exercise/tax liability with 524 shares, increasing direct ownership by 0.34% to 239,738 units (SEC Form 4)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERChief Strategy Officer Sundaram Preethi converted options into 6,667 shares and covered exercise/tax liability with 2,369 shares, increasing direct ownership by 9% to 54,804 units (SEC Form 4)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERChief Commercial Officer Del Carmen Jeffrey converted options into 8,667 shares and covered exercise/tax liability with 3,839 shares, increasing direct ownership by 51% to 14,337 units (SEC Form 4)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERDirector Harper Molly exercised 20,000 shares at a strike of $5.78 and sold $621,920 worth of shares (26,746 units at $23.25), decreasing direct ownership by 74% to 2,360 units (SEC Form 4)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- PRCatalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceCORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Presentation DetailsDate: Monday, January 12, 2026Time: 3:45pm PSTWebcast Link The webcast will be available under the Investors section on the Company's website, www.catalyst